Global Etanercept biosimilar market is expected to grow at rapid pace with strong presence of major players such as Avesthagen, Cipla, LG Life Sciences, Protalix Biotherapeutics, BioXpress Therapeutics, Sandoz, Celltrion, Teva Pharmaceutical Industries, P

InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on 'Global Etanercept Biosimilar Market Assessment – Revenue Forecast, Clinical Trial/Pipeline Analysis, Brand/Originator Drug Historic Revenue and Forecast Till 2027'

Request for ToC/Proposal: https://bit.ly/2WQWeLX

Etanercept is a tumor necrosis factor alpha (TNF-α) inhibitor, an important inflammatory disease mediator in various articular diseases. Etanercept was the first tumour necrosis factor alpha (TNF-α) inhibitor approved for the treatment of rheumatoid arthritis. It is also approved for the treatment of juvenile rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis. Etanercept competitively inhibits the binding of TNF to cell surface receptors and thus make TNF biologically inactive. By doing so, the drug inhibits the pro-inflammatory effects of TNF and thereby leads in a reduction of joint inflammation. Etanercept was developed and marketed by Amgen and Pifzer. The drug was approved by the U.S. Food Drug and Administration in November 1998. It is approved in Europe by European Medicines Agency in February 2000. It is marketed under the trade name of ‘Enbrel’. Expiration of patent and near-term expiration of patent has led to entry of biosimilar into the market. The patent of Enbrel is expired in Europe in August 2015 and will expire in the U.S. in November 2028.

The Etanercept biosimilar market is fragmented/consolidated with presence of many/few players that operates in local as well as international market.
Global Etanercept biosimilar Market reports cover prominent players like Avesthagen, Cipla, LG Life Sciences, Protalix Biotherapeutics, BioXpress Therapeutics, Sandoz, Celltrion, Teva Pharmaceutical Industries, Pfizer, Samsung Bioepis, mAbxience, and among others.

Curious about this latest version of report?

Obtain Report Details @ https://bit.ly/2WQWeLX

Market Segments
• Global Etanercept biosimilar Market Outlook (Revenue, US$ Mn, 2017 - 2027) By Application
o Rheumatoid Arthritis
o Juvenile Rheumatoid Arthritis
o Psoriatic Arthritis
o Plaque Psoriasis
o Ankylosing Spondylitis
• Global Etanercept Biosimilar Market Outlook (Revenue, US$ Mn, 2017 - 2027) By Distribution Channel
o Hospital Pharmacy
o Online Pharmacy
o Retail Pharmacy
o Other Direct Distribution Channels

Why should buy this report:
 To receive a comprehensive analysis of the prospects for global etanercept biosimilar market
 To receive industry overview and future trends etanercept biosimilar market
 To analyze the etanercept biosimilar market drivers and challenges
 To get information on etanercept biosimilar market size and forecast
 To get details on etanercept biosimilar clinical trial/pipeline analysis
 Originator drug historic revenue
 Originator drug key news/industry activities
 Major Mergers & Acquisition in Etanercept biosimilar industry

For More Information @ https://bit.ly/2WQWeLX

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Email us: info@insightaceanalytic.com
Call us: +1 718 593 4405
Pune, Maharashtra 411004

This release was published on openPR.